Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Status:
No longer available
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor
umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
It also stops the patient's immune system from rejecting the donor's stem cells. The donated
stem cells may replace the patient's immune cells and help destroy any remaining cancer or
abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can
also make an immune response against the body's normal cells. Giving tacrolimus and
mycophenolate mofetil before the transplant may stop this from happening.
PURPOSE: This clinical trial is studying how well umbilical cord blood stem cell transplant
works in treating patients with hematologic cancer or other disease.